137 related articles for article (PubMed ID: 1476811)
1. [Proliferation kinetics of human brain tumors by in situ double labeling with bromodeoxyuridine and iododeoxyuridine].
Maeda T; Hoshino T
No To Shinkei; 1992 Sep; 44(9):821-5. PubMed ID: 1476811
[TBL] [Abstract][Full Text] [Related]
2. Cell kinetic analysis of human brain tumors by in situ double labelling with bromodeoxyuridine and iododeoxyuridine.
Hoshino T; Ito S; Asai A; Shibuya M; Prados MD; Dodson BA; Davis RL; Wilson CB
Int J Cancer; 1992 Jan; 50(1):1-5. PubMed ID: 1728598
[TBL] [Abstract][Full Text] [Related]
3. Cell kinetics of glial tumors.
Hoshino T
Rev Neurol (Paris); 1992; 148(6-7):396-401. PubMed ID: 1448658
[TBL] [Abstract][Full Text] [Related]
4. Cell kinetics of rat 9L brain tumors determined by double labeling with iodo- and bromodeoxyuridine.
Asai A; Shibui S; Barker M; Vanderlaan M; Gray JW; Hoshino T
J Neurosurg; 1990 Aug; 73(2):254-8. PubMed ID: 2366082
[TBL] [Abstract][Full Text] [Related]
5. [A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method].
Nagashima T; Hoshino T
No Shinkei Geka; 1984 Aug; 12(9):1007-18. PubMed ID: 6390240
[TBL] [Abstract][Full Text] [Related]
6. A new method for analyzing the cell kinetics of human brain tumors by double labeling with bromodeoxyuridine in situ and with iododeoxyuridine in vitro.
Shibuya M; Ito S; Davis RL; Wilson CB; Hoshino T
Cancer; 1993 May; 71(10):3109-13. PubMed ID: 8490840
[TBL] [Abstract][Full Text] [Related]
7. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.
Shibuya M; Hoshino T; Ito S; Wacker MR; Prados MD; Davis RL; Wilson CB
Neurosurgery; 1992 Apr; 30(4):494-7; discussion 497-8. PubMed ID: 1584346
[TBL] [Abstract][Full Text] [Related]
8. In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling.
Hoshino T; Nagashima T; Murovic JA; Wilson CB; Edwards MS; Gutin PH; Davis RL; DeArmond SJ
J Neurosurg; 1986 Mar; 64(3):453-9. PubMed ID: 3950723
[TBL] [Abstract][Full Text] [Related]
9. Cell proliferation of human leukemia and solid tumors studied with in vivo bromodeoxyuridine and flow cytometry.
Giordano M; Riccardi A; Danova M; Brugnatelli S; Mazzini G
Cancer Detect Prev; 1991; 15(5):391-6. PubMed ID: 1751950
[TBL] [Abstract][Full Text] [Related]
10. Measurement of labeling index of DNA polymerase alpha in human brain tumors. Comparative study with labeling indices of BUdR in vitro and Ki-67.
Nishizaki T; Orita T; Kamiryo T; Akimura T; Kajiwara K; Ikeda N; Ohshita N; Ito H; Sasaki K
Clin Neuropathol; 1993; 12(3):160-3. PubMed ID: 8324965
[TBL] [Abstract][Full Text] [Related]
11. Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors.
Nishizaki T; Orita T; Furutani Y; Ikeyama Y; Aoki H; Sasaki K
J Neurosurg; 1989 Mar; 70(3):379-84. PubMed ID: 2536805
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical double staining with immunogold-silver and alkaline phosphatase to identify nuclear markers of cellular proliferation.
Shibuya M; Ito S; Davis RL; Hoshino T
Biotech Histochem; 1993 Jan; 68(1):17-9. PubMed ID: 8383543
[TBL] [Abstract][Full Text] [Related]
13. Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling.
Cho KG; Hoshino T; Nagashima T; Murovic JA; Wilson CB
J Neurosurg; 1986 Dec; 65(6):790-4. PubMed ID: 3772477
[TBL] [Abstract][Full Text] [Related]
14. Cell-kinetic characteristics of human brain tumors.
Assietti R; Butti G; Magrassi L; Danova M; Riccardi A; Gaetani P
Oncology; 1990; 47(4):344-51. PubMed ID: 2367061
[TBL] [Abstract][Full Text] [Related]
15. [Cell proliferation in human cerebral tumors. In vivo study of 45 cases by incorporation of 5-iododesoxyuridine].
Duprez A; Barat JL; Girard A; Hoffmann M; Hepner H
Neurochirurgie; 1990; 36(3):157-66. PubMed ID: 2234259
[TBL] [Abstract][Full Text] [Related]
16. S-phase fraction, 5-bromo-2'-deoxy-uridine labelling index, duration of S-phase, potential doubling time, and DNA index in benign and malignant brain tumors.
Struikmans H; Rutgers DH; Jansen GH; Tulleken CA; van der Tweel I; Battermann JJ
Radiat Oncol Investig; 1997; 5(4):170-9. PubMed ID: 9327496
[TBL] [Abstract][Full Text] [Related]
17. [Cell kinetic analysis of human brain tumors by bivariate flow cytometric measurement of cellular DNA content and amount of incorporated bromodeoxyuridine].
Okuda Y; Taomoto K; Saya H; Ijichi A; Kudo H; Kokunai T; Tamaki N; Matsumoto S
No To Shinkei; 1989 Apr; 41(4):383-90. PubMed ID: 2765301
[TBL] [Abstract][Full Text] [Related]
18. Final report on the University of California-San Francisco experience with bromodeoxyuridine labeling index as a prognostic factor for the survival of glioma patients.
Lamborn KR; Prados MD; Kaplan SB; Davis RL
Cancer; 1999 Feb; 85(4):925-35. PubMed ID: 10091772
[TBL] [Abstract][Full Text] [Related]
19. Cell kinetics of head and neck cancers.
Kotelnikov VM; Coon JS IV; Haleem A; Taylor S IV; Hutchinson J; Panje W; Caldarelli DD; Griem K; Preisler HD
Clin Cancer Res; 1995 May; 1(5):527-37. PubMed ID: 9816012
[TBL] [Abstract][Full Text] [Related]
20. [A cell kinetic study of human central nervous system tumors with 5-bromodeoxyuridine (BrdU)].
Nagashima T; Hoshino T
No To Shinkei; 1985 Dec; 37(12):1195-201. PubMed ID: 3912000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
